Page 190 - Read Online

Glinsky Genetic signatures of lethal disease in early stage prostate cancer

Figure 1: Natural history of prostate cancer progression in patients’ population from a Swedish watchful waiting cohort with up to
30 years follow-up (A) and classification performance of the 98 genes signature of lethal disease in prostate cancer patients (B-E).
(A) Cancer-specific survival data in the entire watchful waiting cohort are presented to illustrate markedly distinct survival timelines
of non-treated prostate cancer patients diagnosed with different Gleason scores prostate cancer. Kaplan-Meier survival analysis
of the classification performance of the 98 genes GES in the training set (B), test set (C), and pooled cohort of 281 patients (D, E).
Classification threshold 98 genes GES score of 270.43 units was chosen using the training set of 141 prostate cancer patients and
consistently applied in all subsequent validation screens using the Kaplan-Meier survival analysis to stratify the patients into lethal
disease sub-groups (score ≥ 270.43) and moderate/aggressive disease sub-group (score < 270.43). Percent value indicates the
proportion of patients in the lethal disease sub-group. P values indicate the significance of the differences in the numbers of death
events and surviving patients between the groups which was determined using two-sided Fisher’s exact test. GES: gene expression
signatures
182 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ September 21, 2017